AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BLANK CHECKS
Translational Development Acquisition Corp. Ordinary Shares
XNAS · usd
SIC 6770 · BLANK CHECKS
FIGI BBG01S83YTY4
10.81▲ 0.00 (0.00%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
10.81
Day's Range
10.81 – 10.86
52-Week Range
10.41 – 10.95
Volume
1,684
Avg Volume
7,198
Share Statistics
Shares Outstanding
Employees
—
Exchange
XNAS
Listed
2025-02-13
Share count as of August 14, 2026

Translational Development Acquisition Corp. Ordinary Shares (TDAC) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Translational Development Acquisition Corp. Ordinary Shares (TDAC)
What is Translational Development Acquisition Corp. Ordinary Shares's Market Cap?
Translational Development Acquisition Corp. Ordinary Shares's Market Cap is $208.7M, based on as-reported figures from SEC (XBRL) filings.
What is Translational Development Acquisition Corp. Ordinary Shares's Enterprise Value?
Translational Development Acquisition Corp. Ordinary Shares's Enterprise Value is $208.6M, based on as-reported figures from SEC (XBRL) filings.
What is Translational Development Acquisition Corp. Ordinary Shares's Trailing P/E?
Translational Development Acquisition Corp. Ordinary Shares's Trailing P/E is 37.7×, based on as-reported figures from SEC (XBRL) filings.
What is Translational Development Acquisition Corp. Ordinary Shares's Net Income (TTM)?
Translational Development Acquisition Corp. Ordinary Shares's Net Income (TTM) is $5.5M, based on as-reported figures from SEC (XBRL) filings.
What is Translational Development Acquisition Corp. Ordinary Shares's Diluted EPS (TTM)?
Translational Development Acquisition Corp. Ordinary Shares's Diluted EPS (TTM) is 0.29, based on as-reported figures from SEC (XBRL) filings.
What is Translational Development Acquisition Corp. Ordinary Shares's Net Debt?
Translational Development Acquisition Corp. Ordinary Shares's Net Debt is -$85.9K, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · TDACAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue—
YoY growth—+436.5%-97.4%-31.4%
Cost of Revenue—
Gross profit—
% of revenue—27.6%-3785.0%-48.8%
Operating expenses:
Personnel costs—
Professional Fees—
Selling, General and Administrative Expense
Depreciation Expense—
Total operating expenses—
% of revenue—458.3%89618.5%3260.1%
Loss from operations
% of revenue—-430.7%-93403.5%-3308.9%
Other expenses
Interest Expense———
Interest income————
Non-Operating Income (Expense)———
Other income———
Total other expenses (income), net
Net loss before income tax—
Net loss—
% of revenue—-294.7%-141415.2%-3347.3%
Net (Income) Loss attributable to noncontrolling interest—
Net loss attributable to SEGG Media
% of revenue—-393.1%-136063.7%-3226.2%
Earnings Per Share (Basic)—
Earnings Per Share (Diluted)—